Evidence map›Paper›PMID 33251643›Full record

Trial reportEuropean journal of heart failure2021

Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure.

Eva M Boorsma, Joost C Beusekamp, Jozine M Ter Maaten, Sylwia M Figarska, A H Jan Danser, Dirk J van Veldhuisen, Peter van der Meer, Hiddo J L Heerspink, Kevin Damman, Adriaan A Voors

Open access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 4 pooled it
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 4 syntheses or guidelines pooled it, 140 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Observational
  17. Review
  18. Review
  19. Article
  20. Review

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Eva M Boorsma *University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Joost C Beusekamp *University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Jozine M Ter MaatenUniversity of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Sylwia M FigarskaUniversity of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
A H Jan DanserDepartment of Internal Medicine, Division of Pharmacology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
Dirk J van VeldhuisenUniversity of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Peter van der MeerUniversity of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Hiddo J L HeerspinkUniversity of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Kevin DammanUniversity of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Adriaan A VoorsUniversity of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
University of Groningen · NLUniversity Medical Center Groningen · NLErasmus MC · NL

Funding

Boehringer Ingelheim
6 · The paper itself

Abstract

aimsSodium-glucose co-transporter 2 (SGLT2) inhibitors improve clinical outcome in patients with heart failure (HF), but the mechanisms behind their beneficial effects are not yet fully understood. We examined the effects of empagliflozin on renal sodium and glucose handling in patients with acute HF. METHODS AND

resultsThis study was a pre-defined sub-study of a double-blind, randomized, placebo-controlled, multicentre study (EMPA-RESPONSE-AHF). Patients were allocated within 24 h of an acute HF admission to either empagliflozin 10 mg/day (n = 40) or placebo (n = 39) for 30 days. Markers of glucose and sodium handling were measured daily during the first 96 h and at day 30. Patients were 76 (range 38-89) years old and 33% had diabetes. The use of loop diuretics during the first 96 h was similar in both groups. Empagliflozin increased fractional glucose excretion with a peak after 24 h (21.8% vs. 0.1%; P < 0.001), without affecting plasma glucose concentration, while fractional sodium and chloride excretion and urinary osmolality remained unchanged (P >0.3 for all). However, empagliflozin increased plasma osmolality (delta osmolality at 72 h: 5 ± 8 vs. 2 ± 5 mOsm/kg; P = 0.049). Finally, there was an early decline in estimated glomerular filtration rate with empagliflozin vs. placebo (-10 ± 12 vs. -2 ± 12 mL/min/1.73 m

conclusionIn patients with acute HF, empagliflozin increased fractional glucose excretion and plasma osmolality, without affecting fractional sodium excretion or urine osmolality and caused a temporary decline in estimated glomerular filtration rate. This suggests that empagliflozin stimulates osmotic diuresis through increased glycosuria rather than natriuresis in patients with acute HF.

Indexed as

Diabetes Mellitus, Type 2Heart FailureAdultAgedAged, 80 and overBenzhydryl CompoundsGlucoseGlucosidesHumansMiddle AgedSodiumBenzhydryl CompoundsempagliflozinGlucoseGlucosidesSodiumAcute heart failureDiuresisEmpagliflozinKidneySodium-glucose co-transporter 2 inhibitors

Identifiers

PMID33251643
PMCPMC8048437
OpenAlexW3106776335

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.